Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose 5% provides a source of calories and water for hydration, correcting hypoglycemia by increasing blood glucose levels. Sodium chloride 0.45% and potassium chloride 5 m Eq restore electrolyte balance: sodium and chloride are essential for maintenance of extracellular fluid volume and acid-base balance; potassium is critical for neuromuscular function, cardiac contractility, and intracellular osmotic pressure.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Fluid and electrolyte replacement,Treatment of hypokalemia,Correction of metabolic acidosis (as part of balanced solution),Maintenance hydration with minimal caloric supplementation,Off-label: Prevention of ketosis in fasting or catabolic states
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous infusion at a rate determined by fluid and electrolyte requirements; typical adult dose is 1000-2000 m L over 24 hours, not exceeding 50 m L/kg/day.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Dextrose: ~1.5-2.5 minutes (rapid cellular uptake). Sodium/potassium: hours to days (depends on total body stores and renal function); in renal failure, half-life is prolonged.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Dextrose is metabolized via glycolysis and oxidative phosphorylation; excess glucose converted to glycogen or fat. Potassium and sodium are not metabolized but excreted renally; chloride is excreted renally or in sweat.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal: Dextrose is metabolized to CO2 and water, not excreted unchanged; sodium and potassium are primarily excreted renally (>90% of load), with minor fecal loss (<5%).
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Dextrose: negligible. Sodium/potassium: not protein-bound.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Dextrose: ~0.2 L/kg (extracellular fluid). Sodium/potassium: Vd approximates total body water (0.6 L/kg) for potassium; sodium Vd ~0.2 L/kg (extracellular).
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Intravenous: 100% (only route used). Not administered orally for this purpose.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
GFR > 50 m L/min: no adjustment. GFR 10-50 m L/min: reduce dose by 50% or adjust potassium content based on serum levels. GFR < 10 m L/min: avoid use or use with extreme caution; monitor potassium closely; may require potassium restriction.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
Child-Pugh A: no adjustment. Child-Pugh B: monitor potassium levels; reduce potassium content if hyperkalemia risk. Child-Pugh C: avoid potassium-containing solutions unless severe hypokalemia; monitor serum potassium closely.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Intravenous infusion at 5-10 m L/kg/hour initially, adjusted based on serum electrolytes and fluid status; maximum 50 m L/kg/day; potassium component requires weight-based dosing: 0.5-1 m Eq/kg/day for maintenance, not to exceed 3 m Eq/kg/day.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Elderly patients: use lower initial infusion rates (e.g., 50-100 m L/hour) and titrate based on renal function and cardiac status; monitor for fluid overload and electrolyte imbalances; reduce potassium content if renal impairment present.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
None
None.
Monitor serum potassium, glucose, and fluid balance closely; avoid in patients with severe renal impairment or oliguria; risk of hyperkalemia with rapid infusion in renal dysfunction; contains aluminum (may accumulate with prolonged use); use with caution in heart failure, pulmonary edema, or hyperosmolar states.
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hyperkalemia, hypernatremia, severe renal impairment with oliguria, anuria, or impaired potassium excretion; clinically significant fluid overload; hypersensitivity to any component; patients with sickle cell disease (risk of thrombosis).
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
Avoid high-potassium foods (e.g., bananas, oranges, potatoes, spinach) and salt substitutes containing potassium chloride to prevent hyperkalemia. No other food interactions.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
No known teratogenic risk. Dextrose, sodium chloride, and potassium chloride are normal blood constituents. At clinically relevant doses, no fetal harm is expected in any trimester.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Safe during breastfeeding. Components are normal plasma constituents and enter breast milk in negligible amounts. M/P ratio not applicable.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
No specific dose adjustment required for pregnancy. Monitor for gestational diabetes or preeclampsia; adjust infusion rate to avoid fluid overload or electrolyte imbalances. Consider increased volume of distribution and glomerular filtration rate in pregnancy only if clinically significant.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Restricted in patients with hyperkalemia, severe renal impairment, or oliguria. Use with caution in heart failure, pulmonary edema, or conditions with sodium retention. Monitor serum potassium, renal function, and fluid balance. Contains 5.5 m Eq/L potassium; rate must not exceed 10-20 m Eq/h via peripheral line to avoid phlebitis and cardiac effects.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
This solution provides fluids, sugar, and potassium to correct dehydration and electrolyte imbalances.,Report any signs of fluid overload (swelling, shortness of breath), hyperkalemia (muscle weakness, palpitations), or infusion site reactions.,Do not consume additional potassium supplements or salt substitutes without consulting your doctor.,Tell your healthcare provider if you have kidney disease, heart problems, or are on a potassium-restricted diet.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose 5% provides a source of calories and water for hydration, correcting hypoglycemia by increasing blood glucose levels. Sodium chloride 0.45% and potassium chloride 5 m Eq restore electrolyte balance: sodium and chloride are essential for maintenance of extracellular fluid volume and acid-base balance; potassium is critical for neuromuscular function, cardiac contractility, and intracellular osmotic pressure.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER is: Intravenous infusion at a rate determined by fluid and electrolyte requirements; typical adult dose is 1000-2000 m L over 24 hours, not exceeding 50 m L/kg/day.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER is classified as Category A/B. No known teratogenic risk. Dextrose, sodium chloride, and potassium chloride are normal blood constituents. At clinically relevant doses, no fetal harm is expected in any trimester. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.